About the speaker
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), where he focused on network biology applications using high-throughput experimental assays and network analysis. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012).
Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in 2011, and was selected as Professor of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, University of Oslo, in 2019.
Abstract
This talk describes an experimental-computational approach, based single-cell transcriptomics and machine learning, to identify patient-tailored therapies for selective co-inhibition of cancer clones.
Translational applications in both solid and hematological cancers will be presented.